Table 2.
Cardiovascular disease outcomes of hypertension patients with different antihypertensive treatments
| Antihypertensive treatment | Hypertension (n) | Cardiovascular disease (n) | Percentage of cardiovascular disease outcomes (%) | P value | |
|---|---|---|---|---|---|
| Regular | 309 | 182 | 37.07 | 12.491 | < 0.001 |
| Irregular | 49 | 62 | 55.86 | ||
| Single-drug | 97 | 75 | 43.60 | 9.170 | 0.010 |
| Two-drug | 150 | 63 | 29.58 | ||
| Multi-drug | 62 | 44 | 41.51 | ||
| Single-drug | 97 | 75 | 43.60 | 7.544 | 0.006 |
| Two-drug | 150 | 63 | 29.58 | ||
| Two-drug | 150 | 63 | 29.58 | 4.001 | 0.045 |
| Multi-drug | 62 | 44 | 41.51 | ||
| Single-drug | 97 | 75 | 43.60 | 0.048 | 0.827 |
| Multi-drug | 62 | 44 | 41.51 | ||
| ACEis/ARBs + Beta-blockers | 20 | 12 | 37.5 | 8.853 | 0.031 |
| ACEis/ARBs + CCBs | 73 | 18 | 19.8 | ||
| ACEis/ARBs + Diuretics | 24 | 8 | 25.0 | ||
| Beta-blockers + CCBs | 30 | 21 | 41.1 |
P values < 0.05 are written in italics
Values shown are n or (%). P values were calculated by chi-squared test, or Fisher’s exact test, as appropriate
Abbreviations: n Number, ACEi Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor antagonist, CCB Calcium channel receptor blocker